BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31703102)

  • 1. Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation.
    Scheich S; Enßle JC; Mücke VT; Acker F; Aspacher L; Wolf S; Wilke AC; Weber S; Brunnberg U; Serve H; Steffen B
    PLoS One; 2019; 14(11):e0225035. PubMed ID: 31703102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Navarro WH; Loberiza FR; Bajorunaite R; van Besien K; Vose JM; Lazarus HM; Rizzo JD
    Biol Blood Marrow Transplant; 2006 May; 12(5):541-51. PubMed ID: 16635789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.
    Urbano-Ispizua A; Pavletic SZ; Flowers ME; Klein JP; Zhang MJ; Carreras J; Montoto S; Perales MA; Aljurf MD; Akpek G; Bredeson CN; Costa LJ; Dandoy C; Freytes CO; Fung HC; Gale RP; Gibson J; Hamadani M; Hayashi RJ; Inamoto Y; Inwards DJ; Lazarus HM; Maloney DG; Martino R; Munker R; Nishihori T; Olsson RF; Rizzieri DA; Reshef R; Saad A; Savani BN; Schouten HC; Smith SM; Socié G; Wirk B; Yu LC; Saber W
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1746-53. PubMed ID: 25981509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
    Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
    Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Brunstein CG; Pasquini MC; Kim S; Fei M; Adekola K; Ahmed I; Aljurf M; Agrawal V; Auletta JJ; Battiwalla M; Bejanyan N; Bubalo J; Cerny J; Chee L; Ciurea SO; Freytes C; Gadalla SM; Gale RP; Ganguly S; Hashmi SK; Hematti P; Hildebrandt G; Holmberg LA; Lahoud OB; Landau H; Lazarus HM; de Lima M; Mathews V; Maziarz R; Nishihori T; Norkin M; Olsson R; Reshef R; Rotz S; Savani B; Schouten HC; Seo S; Wirk BM; Yared J; Mineishi S; Rogosheske J; Perales MA
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):480-487. PubMed ID: 30423481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
    Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
    Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
    Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
    Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation.
    Urbain P; Birlinger J; Ihorst G; Biesalski HK; Finke J; Bertz H
    Ann Hematol; 2013 Jan; 92(1):111-9. PubMed ID: 22968661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
    Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Calderón-Cabrera C; Márquez-Malaver FJ; de la Cruz-Vicente F; Falantes F; Carrillo E; Parody R; Montero I; González Campos J; Martino ML; Carmona M; Pérez-Simón JA; Espigado I
    Transplant Proc; 2013; 45(10):3665-7. PubMed ID: 24314990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.